Trials that use: Kaplan-Meier estimation
New to this method? Read the tutorial →
471 results
- A Study of the Efficacy and Safety of Bevacizumab in Chinese Women With Newly Diagnosed, Previously Untreated Stage III or Stage IV Epithelial Ovarian, Fallopian Tube, or Primary Peritoneal Cancer: Complete Statistical AnalysisIndependent statistical analysis of A Study of the Efficacy and Safety of Bevacizumab in Chinese Women With Newly Diagnosed, Previously Untreated Stage III or Stage IV Epithelial Ovarian, Fallopian Tube, or Primary…
- A Study of Trastuzumab Emtansine Versus Taxane in Participants With Human Epidermal Growth Factor Receptor 2 (HER2)-Positive Advanced Gastric Cancer: Complete Statistical AnalysisIndependent statistical analysis of A Study of Trastuzumab Emtansine Versus Taxane in Participants With Human Epidermal Growth Factor Receptor 2 (HER2)-Positive Advanced Gastric Cancer: primary endpoint results, effect estimate with confidence interval,…
- A Study of Vismodegib (GDC-0449, Hedgehog Pathway Inhibitor) As Maintenance Therapy in Patients With Ovarian Cancer in a Second or Third Complete Remission: Complete Statistical AnalysisIndependent statistical analysis of A Study of Vismodegib (GDC-0449, Hedgehog Pathway Inhibitor) As Maintenance Therapy in Patients With Ovarian Cancer in a Second or Third Complete Remission: primary endpoint results, effect estimate…
- A Study of Vismodegib (GDC-0449, Hedgehog Pathway Inhibitor) With Concurrent Chemotherapy and Bevacizumab As First-Line Therapy for Metastatic Colorectal Cancer: Complete Statistical AnalysisIndependent statistical analysis of A Study of Vismodegib (GDC-0449, Hedgehog Pathway Inhibitor) With Concurrent Chemotherapy and Bevacizumab As First-Line Therapy for Metastatic Colorectal Cancer: primary endpoint results, effect estimate with confidence interval,…
- A Study of Xeloda (Capecitabine) in Women With HER2-Negative Metastatic Breast Cancer: Complete Statistical AnalysisIndependent statistical analysis of A Study of Xeloda (Capecitabine) in Women With HER2-Negative Metastatic Breast Cancer: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety, based on ClinicalTrials.gov…
- A Study To Assess The Safety And Efficacy Of SU11248 In Patients With Gastrointestinal Stromal Tumor(GIST): Complete Statistical AnalysisIndependent statistical analysis of A Study To Assess The Safety And Efficacy Of SU11248 In Patients With Gastrointestinal Stromal Tumor(GIST): primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and…
- A Study to Assess the Safety and Efficacy of the VEGFR-FGFR-PDGFR Inhibitor, Lucitanib, Given to Patients With Metastatic Breast Cancer: Complete Statistical AnalysisIndependent statistical analysis of A Study to Assess the Safety and Efficacy of the VEGFR-FGFR-PDGFR Inhibitor, Lucitanib, Given to Patients With Metastatic Breast Cancer: primary endpoint results, effect estimate with confidence interval,…
- A Study to Assess Treatment With 2 Different Dosing Schedules of Trabectidin Administered to Patients With Advanced Cancer: Complete Statistical AnalysisIndependent statistical analysis of A Study to Assess Treatment With 2 Different Dosing Schedules of Trabectidin Administered to Patients With Advanced Cancer: primary endpoint results, effect estimate with confidence interval, sample-size planning…
- A Study to Evaluate the Efficacy and Safety of Trastuzumab Emtansine Versus the Combination of Trastuzumab Plus Docetaxel in Patients With HER2-positive Breast Cancer: Complete Statistical AnalysisIndependent statistical analysis of A Study to Evaluate the Efficacy and Safety of Trastuzumab Emtansine Versus the Combination of Trastuzumab Plus Docetaxel in Patients With HER2-positive Breast Cancer: primary endpoint results, effect…
- A Study to Evaluate the Safety, Tolerability, and Efficacy of the Addition of Omarigliptin (MK-3102) to Participants With Type 2 Diabetes Mellitus Who Have Inadequate Glycemic Control on Metformin Therapy (MK-3102-024): Complete Statistical AnalysisIndependent statistical analysis of A Study to Evaluate the Safety, Tolerability, and Efficacy of the Addition of Omarigliptin (MK-3102) to Participants With Type 2 Diabetes Mellitus Who Have Inadequate Glycemic Control on…
- A Study to Evaluate the Use and Safety of CARDIOLITE® in Pediatric Patients With Kawasaki Disease: Complete Statistical AnalysisIndependent statistical analysis of A Study to Evaluate the Use and Safety of CARDIOLITE® in Pediatric Patients With Kawasaki Disease: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and…
- A Study to Learn About Novel Hormonal Therapies (NHTs) for Metastatic Castration-sensitive Prostate Cancer (mCSPC) in People Who Were in the Armed Forces: Complete Statistical AnalysisIndependent statistical analysis of A Study to Learn About Novel Hormonal Therapies (NHTs) for Metastatic Castration-sensitive Prostate Cancer (mCSPC) in People Who Were in the Armed Forces: primary endpoint results, effect estimate…
- A Study to Learn About Novel Hormonal Therapies in People With Metastatic Castration-Sensitive Prostate Cancer (mCSPC): Complete Statistical AnalysisIndependent statistical analysis of A Study to Learn About Novel Hormonal Therapies in People With Metastatic Castration-Sensitive Prostate Cancer (mCSPC): primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and…
- A Trial of FANG™ Vaccine for Participants With Ovarian Cancer: Complete Statistical AnalysisIndependent statistical analysis of A Trial of FANG™ Vaccine for Participants With Ovarian Cancer: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety, based on ClinicalTrials.gov results (NCT01309230).
- A Trial of Telemonitoring in Adults With Heart Failure: Complete Statistical AnalysisIndependent statistical analysis of A Trial of Telemonitoring in Adults With Heart Failure: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety, based on ClinicalTrials.gov results (NCT01393314).
- A Trial to Confirm the Efficacy and Safety of Dasiglucagon in the Treatment of Hypoglycemia in Type 1 Diabetes Subjects: Complete Statistical AnalysisIndependent statistical analysis of A Trial to Confirm the Efficacy and Safety of Dasiglucagon in the Treatment of Hypoglycemia in Type 1 Diabetes Subjects: primary endpoint results, effect estimate with confidence interval,…
- A Trial to Evaluate the Efficacy, Safety & Tolerability of Brexpiprazole in the Maintenance Treatment of Adults With Major Depressive Disorder: Complete Statistical AnalysisIndependent statistical analysis of A Trial to Evaluate the Efficacy, Safety & Tolerability of Brexpiprazole in the Maintenance Treatment of Adults With Major Depressive Disorder: primary endpoint results, effect estimate with confidence…
- A-PREDICTIndependent statistical analysis of A Phase II Study of Axitinib in Patients With Metastatic Renal Cell Cancer Unsuitable for Nephrectomy: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and…
- Abatacept for Treating Adults With Giant Cell Arteritis and Takayasu’s Arteritis: Complete Statistical AnalysisIndependent statistical analysis of Abatacept for Treating Adults With Giant Cell Arteritis and Takayasu's Arteritis: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety, based on ClinicalTrials.gov results…
- ABI-007 In Combination With Bevacizumab in Women With Metastatic Breast Cancer: Complete Statistical AnalysisIndependent statistical analysis of ABI-007 In Combination With Bevacizumab in Women With Metastatic Breast Cancer: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety, based on ClinicalTrials.gov results…
- ACCELERATEComplete statistical analysis of ACCELERATE (NCT01687998), a randomized phase 3 study of evacetrapib versus placebo in high-risk vascular disease, including trial design, composite cardiovascular endpoints, Cox modeling, ANOVA, confidence intervals, p-values, and…
- ACTT-3Independent statistical analysis of ACTT-3, the phase 3 randomized trial of remdesivir plus interferon beta-1a versus remdesivir plus placebo in COVID-19, including time-to-recovery, subgroup hazard ratios, safety, and statistical interpretation.
- ADAURAIndependent statistical analysis of the ADAURA phase 3 trial of AZD9291 versus placebo after complete tumour resection in stage IB-IIIA non-small cell lung carcinoma, including disease-free survival, overall survival, trial design, methodology,…
- ADI-PEG 20 in Combination With Gemcitabine and Docetaxel for the Treatment of Soft Tissue Sarcoma, Osteosarcoma, Ewing’s Sarcoma, and Small Cell Lung Cancer: Complete Statistical AnalysisIndependent statistical analysis of ADI-PEG 20 in Combination With Gemcitabine and Docetaxel for the Treatment of Soft Tissue Sarcoma, Osteosarcoma, Ewing's Sarcoma, and Small Cell Lung Cancer: primary endpoint results, effect estimate…
- Adjunct Methadone to Decrease the Duration of Mechanical Ventilation in the Medical Intensive Care Unit: Complete Statistical AnalysisIndependent statistical analysis of Adjunct Methadone to Decrease the Duration of Mechanical Ventilation in the Medical Intensive Care Unit: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety,…
- ADVANCEIndependent statistical analysis of the phase 3 ADVANCE trial of peginterferon beta-1a versus placebo in relapsing multiple sclerosis, covering negative binomial rate ratios for annualized relapse rate, Cox hazard ratios, lesion mean…
- AFFIRMComplete statistical analysis of the AFFIRM phase 3 trial of enzalutamide versus placebo in patients with castration-resistant prostate cancer previously treated with docetaxel-based chemotherapy, including overall survival, secondary time-to-event endpoints, response measures,…
- AGILEComplete statistical analysis of the randomized phase 3 AGILE trial of AG-120 (ivosidenib) plus azacitidine versus placebo plus azacitidine in previously untreated acute myeloid leukemia with an IDH1 mutation.
- ALTA-3Independent statistical analysis of A Study of Brigatinib Compared to Alectinib in Adults With Non-Small-Cell Lung Cancer: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety, based on…
- ALTISSIMOIndependent statistical analysis of A Depot Formulation of Sunitinib Malate (GB-102) Compared to Aflibercept in Subjects With Wet AMD: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety,…
- AMPLITUDE-OIndependent statistical analysis of the phase 3 AMPLITUDE-O trial of efpeglenatide in people with type 2 diabetes, including randomized design, time-to-event endpoints, non-inferiority and superiority analyses, hazard ratios, confidence intervals, and statistical…
- An Investigational Drug, PF-02341066 Is Being Studied Versus Standard Of Care In Patients With Advanced Non-Small Cell Lung Cancer With A Specific Gene Profile Involving The Anaplastic Lymphoma Kinase (ALK) Gene: Complete Statistical AnalysisIndependent statistical analysis of An Investigational Drug, PF-02341066 Is Being Studied Versus Standard Of Care In Patients With Advanced Non-Small Cell Lung Cancer With A Specific Gene Profile Involving The Anaplastic Lymphoma…
- An Open-label Study of GSK1120212 Compared With Docetaxel in Stage IV KRAS-mutant Non-small Cell Lung Cancer: Complete Statistical AnalysisIndependent statistical analysis of An Open-label Study of GSK1120212 Compared With Docetaxel in Stage IV KRAS-mutant Non-small Cell Lung Cancer: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and…
- An Open-Label, Randomized, Phase 3 Trial of Nivolumab Versus Investigator’s Choice Chemotherapy as First-Line Therapy for Stage IV or Recurrent PD-L1+ Non-Small Cell Lung Cancer (CheckMate 026): Complete Statistical AnalysisIndependent statistical analysis of An Open-Label, Randomized, Phase 3 Trial of Nivolumab Versus Investigator's Choice Chemotherapy as First-Line Therapy for Stage IV or Recurrent PD-L1+ Non-Small Cell Lung Cancer (CheckMate 026): primary…
- Analytical Treatment Interruption (ATI) to Assess the Immune System’s Ability to Control HIV in Participants Who Became HIV-infected During the HVTN 703/HPTN 081 AMP Study: Complete Statistical AnalysisIndependent statistical analysis of Analytical Treatment Interruption (ATI) to Assess the Immune System's Ability to Control HIV in Participants Who Became HIV-infected During the HVTN 703/HPTN 081 AMP Study: primary endpoint results,…
- ANGELIndependent statistical analysis of A Study to Evaluate Rivoceranib Plus Best Supportive Care Compared to Placebo Plus Best Supportive Care in Participants With Gastric Cancer: primary endpoint results, effect estimate with confidence…
- ARAMISIndependent statistical analysis of the phase 3 ARAMIS trial of darolutamide versus placebo in men with high-risk non-metastatic castration-resistant prostate cancer, including metastasis-free survival, overall survival, time-to-event methods, and statistical interpretation.
- ARASENSIndependent statistical analysis of ARASENS, the randomized phase 3 trial of darolutamide plus standard androgen deprivation therapy and docetaxel in metastatic hormone-sensitive prostate cancer, including time-to-event methodology, reported hazard ratios, confidence intervals,…
- AREDS2A complete statistical analysis of AREDS2, the randomized phase 3 trial evaluating lutein/zeaxanthin and DHA/EPA in people at moderate to high risk for progression of age-related macular degeneration, including time-to-event methodology, hazard…
- ARIEL3Independent statistical analysis of the phase 3 ARIEL3 trial of rucaparib as switch maintenance after platinum in relapsed high-grade serous or endometrioid ovarian cancer, including trial design, progression-free survival, Cox modeling, hazard…
- ARISTOTLEIndependent statistical analysis of ARISTOTLE (NCT00412984), including trial design, time-to-event endpoints, Cox proportional-hazards methodology, hazard ratios, confidence intervals, safety results, and statistical interpretation.
- ARRIVEIndependent statistical analysis of A Study to Assess the Efficacy and Safety of Enteric-Coated Acetylsalicylic Acid in Patients at Moderate Risk of Cardiovascular Disease: primary endpoint results, effect estimate with confidence interval,…
- ARTEMIS-IPFIndependent statistical analysis of ARTEMIS-IPF, the randomized phase 3 trial of ambrisentan versus placebo in idiopathic pulmonary fibrosis, including its time-to-event endpoint, hazard ratio, secondary analyses, statistical methods, and interpretation.
- ASCENTIndependent statistical analysis of ASCENT, a randomized phase 3 trial of sacituzumab govitecan versus Treatment of Physician's Choice in participants with refractory or relapsed metastatic triple-negative breast cancer.
- ASCLEPIOS IAn independent statistical analysis of ASCLEPIOS I, the phase 3 double-blind comparison of ofatumumab and teriflunomide in relapsing multiple sclerosis, covering the negative binomial relapse-rate analysis, Cox models for pooled disability endpoints,…
- ASCLEPIOS IIAn independent statistical analysis of ASCLEPIOS II, the phase 3 trial of subcutaneous ofatumumab versus teriflunomide in relapsing multiple sclerosis: negative binomial annualized relapse rate, Cox models for confirmed disability, pooled analyses…
- ASPECCTIndependent statistical analysis of ASPECCT, the randomized phase 3 comparison of panitumumab and cetuximab in patients with KRAS wild-type metastatic colorectal cancer, including non-inferiority analysis, hazard ratios, response, patient-reported outcomes, and safety.
- ASPENIndependent statistical analysis of the phase 3 ASPEN trial of brensocatib 10 mg and 25 mg versus placebo in non-cystic fibrosis bronchiectasis, covering negative binomial rate ratios for pulmonary exacerbations, Cox, logistic…
- Assess the Long Term Efficacy and Safety of Ruxolitinib Cream in Participants With Vitiligo: Complete Statistical AnalysisIndependent statistical analysis of Assess the Long Term Efficacy and Safety of Ruxolitinib Cream in Participants With Vitiligo: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety, based…
- Assessing PA-824 for Tuberculosis (the APT Trial): Complete Statistical AnalysisIndependent statistical analysis of Assessing PA-824 for Tuberculosis (the APT Trial): primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety, based on ClinicalTrials.gov results (NCT02256696).